138 related articles for article (PubMed ID: 1319460)
41. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis.
Naber KG;
Int J Antimicrob Agents; 2002 Jul; 20(1):18-27. PubMed ID: 12127707
[TBL] [Abstract][Full Text] [Related]
42. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
Yoshizumi S; Takahashi Y; Murata M; Domon H; Furuya N; Ishii Y; Matsumoto T; Ohno A; Tateda K; Miyazaki S; Yamaguchi K
J Antimicrob Chemother; 2001 Jul; 48(1):137-40. PubMed ID: 11418525
[TBL] [Abstract][Full Text] [Related]
43. Temafloxacin: an overview.
Pankey GA
Am J Med; 1991 Dec; 91(6A):166S-172S. PubMed ID: 1662889
[TBL] [Abstract][Full Text] [Related]
44. Quinolones in dermatology.
Sable D; Murakawa GJ
Dis Mon; 2004 Jul; 50(7):381-94. PubMed ID: 15280869
[No Abstract] [Full Text] [Related]
45. Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
Arai S; Gohara Y; Akashi A; Kuwano K; Nishimoto M; Yano T; Oizumi K; Takeda K; Yamaguchi T
Antimicrob Agents Chemother; 1993 Feb; 37(2):287-92. PubMed ID: 8383942
[TBL] [Abstract][Full Text] [Related]
46. Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole.
Nicolle LE; Louie TJ; Dubois J; Martel A; Harding GK; Sinave CP
Antimicrob Agents Chemother; 1994 Jun; 38(6):1368-73. PubMed ID: 8092839
[TBL] [Abstract][Full Text] [Related]
47. Bone marrow suppression: a side effect of ciprofloxacin therapy.
Chaudhry M; Tarneja N; Gundale A; Roa D; Levey R
Am J Ther; 2010; 17(5):e167-8. PubMed ID: 20844342
[TBL] [Abstract][Full Text] [Related]
48. [Ciprofloxacin and therapy of urinary tract infections, including those due to Staphylococcus saprophyticus].
Ivanov DV; Budanov SV
Antibiot Khimioter; 2006; 51(9-10):61-71. PubMed ID: 18030794
[TBL] [Abstract][Full Text] [Related]
49. Laboratory and clinical study of balofloxacin (Q-35), a new fluoroquinolone, in urinary tract infection.
Suzuki K; Horiba M; Ishikawa K; Katoh S; Naide Y; Yanaoka M; Andoh S
Drugs; 1995; 49 Suppl 2():376-8. PubMed ID: 8549367
[No Abstract] [Full Text] [Related]
50. The role of temafloxacin in the community setting: an overview.
Ball P
J Antimicrob Chemother; 1991 Dec; 28 Suppl C():121-30. PubMed ID: 1664825
[TBL] [Abstract][Full Text] [Related]
51. [The chemotherapeutic efficacy of ciprofloxacin and lomefloxacin in the inhalation method of infecting white mice with tularemia].
D'iakov SI; Bubnov VP; Lebedeva IK; Sidorenko SV; Moskalenko VI
Antibiot Khimioter; 2000; 45(6):17-20. PubMed ID: 10904804
[TBL] [Abstract][Full Text] [Related]
52. [Use of fluoroquinolones in rheumatology].
Belov BS; Shubin SV; Nasonova VA; Soldatova SI; Tarasova GM; Urumova MM; Ushakova MA; Anan'eva LP
Vestn Ross Akad Med Nauk; 1996; (12):12-5. PubMed ID: 9102072
[TBL] [Abstract][Full Text] [Related]
53. A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI.
McCue JD; Gaziano P; Orders D
Drugs; 1995; 49 Suppl 2():368-73. PubMed ID: 8549365
[No Abstract] [Full Text] [Related]
54. Initial clinical experience with clinafloxacin in the treatment of serious infections.
Tack KJ; McGuire NM; Eiseman IA
Drugs; 1995; 49 Suppl 2():488-91. PubMed ID: 8549411
[No Abstract] [Full Text] [Related]
55. Appropriateness of fluoroquinolones for therapy of urinary tract infection.
Johnson JR
Arch Intern Med; 2003 Jul; 163(13):1616-7; author reply 1618. PubMed ID: 12860590
[No Abstract] [Full Text] [Related]
56. An unlikely childhood overdose: temafloxacin.
Muñiz AE
Pediatr Emerg Care; 1996 Jun; 12(3):215-6. PubMed ID: 8806150
[No Abstract] [Full Text] [Related]
57. Clinical role of the quinolones today and in the future.
Waldvogel FA
Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1075-9. PubMed ID: 2620674
[No Abstract] [Full Text] [Related]
58. Temafloxacin as prophylactic agent in neutropenic patients.
al-Wali WI; Wilcox MH; Winstanley TG; Douglas CW; Spencer RC
J Antimicrob Chemother; 1992 Sep; 30(3):402-4. PubMed ID: 1333466
[No Abstract] [Full Text] [Related]
59. Newer quinolones in the long term prophylaxis of recurrent urinary tract infections (UTI).
Krcméry S; Hromec J; Tvrdikova M; Hassan M; Gulla D
Drugs; 1999; 58 Suppl 2():99-102. PubMed ID: 10553716
[TBL] [Abstract][Full Text] [Related]
60. Importance of sulfonamide moiety in current and future therapy.
Parasca OM; Gheaţă F; Pânzariu A; Geangalău I; Profire L
Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):558-64. PubMed ID: 24340546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
